FDA
-
-
-
-
-
-
-
Larimar files first BLA module for Friedreich's ataxia drug
-
-
-
-
-
-
-
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
-
-
-
-
-
-
-
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Larimar Therapeutics (LRMR)
-
-
-
-
-
-
-
Citi on Larimar Therapeutics (LRMR): 'We are buyers on today’s weakness'
-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on Larimar Therapeutics (LRMR), PT $14
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Larimar Therapeutics (LRMR)
-
334,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


